Memantine vs Pembrolizumab

## Memantine vs Pembrolizumab: Overview

This comparison examines the pharmacological differences between **Memantine** and **Pembrolizumab**.

## Mechanism of Action

**Memantine**: Non-competitive NMDA receptor antagonist.

**Pembrolizumab**: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

## Pharmacokinetics

**Half-life**: Memantine — 60-80 hours; Pembrolizumab — 26 days.

## Chemical Properties

**Molecular Formula**: Memantine — C12H21N; Pembrolizumab — N/A.

**Molecular Weight**: Memantine — 179.3080 g/mol; Pembrolizumab — N/A.

**Type**: Memantine — Small molecule; Pembrolizumab — Antibody.